EGFR and Stroke: The study found that CADASIL patients with an epidermal growth factor like-repeat (EGFr) domain 7–34 pathogenic variant had 12-year-later age at onset of stroke and longer survival time than patients with an EGFr domain 1–6 variant (Rutten et al., 2019).